I agree that this site is using cookies. You can find further informations here.
X
van Amerongen, Rosa A.
17  results:
Search for persons X
?
1

Human iPSC-derived preclinical models to identify toxicity ..:

van Amerongen, Rosa A. ; Morton, Laura T. ; Chaudhari, Umesh G....
Molecular Therapy - Methods & Clinical Development.  28 (2023)  - p. 249-261 , 2023
Link: https://doi.org/10.1016/..
 
?
2

PRAME and CTCFL-reactive TCRs for the treatment of ovarian ..:

van Amerongen, Rosa A. ; Tuit, Sander ; Wouters, Anne K....
Frontiers in Immunology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

WT1-specific TCRs directed against newly identified peptide..:

van Amerongen, Rosa A ; Hagedoorn, Renate S ; Remst, Dennis F G...
Journal for ImmunoTherapy of Cancer.  10 (2022)  6 - p. e004409 , 2022
Link: https://doi.org/10.1136/..
 
?
4

Exosomes derived from mesenchymal non-small cell lung cance..:

Lobb, Richard J. ; van Amerongen, Rosa ; Wiegmans, Adrian...
International Journal of Cancer.  141 (2017)  3 - p. 614-620 , 2017
Link: https://doi.org/10.1002/..
 
?
5

Oncogenic transformation of lung cells results in distinct ..:

Lobb, Richard J. ; Hastie, Marcus L. ; Norris, Emma L....
PROTEOMICS.  17 (2017)  23-24 - p. , 2017
Link: https://doi.org/10.1002/..
 
?
6

Next-generation sequencing in NSCLC and melanoma patients: ..:

van Amerongen, Rosa ; P Retèl, Valesca ; Coupé, Veerle MH...
ecancermedicalscience.  10 (2016)  - p. , 2016
Link: https://doi.org/10.3332/..
 
?
7

CD45RA, a specific marker for leukaemia stem cell sub‐popul..:

Kersten, Bas ; Valkering, Matthijs ; Wouters, Rolf...
British Journal of Haematology.  173 (2016)  2 - p. 219-235 , 2016
Link: https://doi.org/10.1111/..
 
?
8

PRAME and CTCFL-reactive TCRs for the treatment of ovarian ..:

van Amerongen, Rosa A ; Tuit, Sander ; Wouters, Anne K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070997/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Human iPSC-derived preclinical models to identify toxicity ..:

van Amerongen, Rosa A ; Morton, Laura T ; Chaudhari, Umesh G...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931760/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
10

WT1-specific TCRs directed against newly identified peptide..:

van Amerongen, Rosa A ; Hagedoorn, Renate S ; Remst, Dennis F G...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214430/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Table_2_PRAME and CTCFL-reactive TCRs for the treatment of ..:

Rosa A. van Amerongen ; Sander Tuit ; Anne K. Wouters...
doi:10.3389/fimmu.2023.1121973.s004.  , 2023
Link: https://doi.org/10.3389/..
 
?
12

DataSheet_2_PRAME and CTCFL-reactive TCRs for the treatment..:

Rosa A. van Amerongen ; Sander Tuit ; Anne K. Wouters...
doi:10.3389/fimmu.2023.1121973.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

PRAME and CTCFL-reactive TCRs for the treatment of ovarian ..:

Rosa A. van Amerongen ; Sander Tuit ; Anne K. Wouters...
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121973/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
14

Human iPSC-derived preclinical models to identify toxicity ..:

Rosa A. van Amerongen ; Laura T. Morton ; Umesh G. Chaudhari...
http://www.sciencedirect.com/science/article/pii/S2329050123000074.  , 2023
Link: https://doi.org/10.1016/..
 
?
15

Table_1_PRAME and CTCFL-reactive TCRs for the treatment of ..:

Rosa A. van Amerongen ; Sander Tuit ; Anne K. Wouters...
doi:10.3389/fimmu.2023.1121973.s003.  , 2023
Link: https://doi.org/10.3389/..
 
1-15